Plerixafor Added to Chemotherapy Plus G-CSF Is Safeand Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma orLymphoma

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 2, 2012, Pages 241-249

  Attolico, Immacolata ^a   Pavone, Vincenzo ^b   Ostuni, Angelo ^b   Rossini, Bernardo ^b   Musso, Maurizio ^c   Crescimanno, Alessandra ^c   Martino, Massimo ^d   Iacopino, Pasquale ^d   Milone, Giuseppe ^e   Tedeschi, Patrizia ^e   Coluzzi, Sabrina ^a   Nuccorini, Roberta ^a   Pascale, Sara ^a   Di Nardo, Elvira ^f   Olivieri, Attilio ^a  

^a SAN CARLO HOSPITAL   (Italy)

^b Divisione di Ematologia   (Italy)

^c LA MADDALENA CANCER CENTER   (Italy)

^d BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^e UO Ematologia Ospedale Ferrarotto   (Italy)

^f UNIVERSITY OF BASILICATA   (Italy)

Author keywords

Autologous stem cell transplantation; PBSC mobilization; Plerixafor; Poor mobilizers

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FOTEMUSTINE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; PLERIXAFOR; THIOTEPA;

ADULT; AGED; AGING; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HODGKIN DISEASE; HUMAN; LONG TERM CARE; LYMPHOMA; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; STEM CELL MOBILIZATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD34; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOVERY OF FUNCTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84855589093     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.014     Document Type: Article

References (47)

1. Wuchter P., Ran D., Bruckner T., et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010, 16:490-499.
2. Bender J.G., To L.B., Williams S., et al. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992, 1:329-341.
3. Klaus J., Herrmann D., Breitkreutz I., et al. Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 2007, 78:21-28.
4. Pusic I., Jiang S.Y., Landua S., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologus transplantation. Biol Blood Marrow Transplant 2008, 14:1045-1056.
5. Jillella A.P., Ustun C. What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?. Stem Cells Dev 2004, 13:598-606.
6. Olivieri A., Offidani M., Montanari M., et al. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 1998, 83:329-337.
7. Watts M.J., Sullivan A.M., Jamieson E., et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997, 15:535-546.
8. van der Wall E., Richel D.J., Holtkamp M.J., et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol 1994, 5:795-802.
9. Scheid C., Draube A., Reiser M., et al. Using at least 5 × 10(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant 1999, 23:1177-1181.
10. Pavone V., Gaudio F., Console G., et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37:719-724.
11. Koc O.N., Gerson S.L., Cooper B.W., et al. Randomized cross-over trial of progenitor-cell mobilization: high dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versusgranulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000, 18:1824-1830.
12. Narayanasami U., Kanteti R., Morelli J., et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001, 98:2059-2064.
13. Spitzer G., Adkins D., Mathews M., et al. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 1997, 20:921-930.
14. Demirer T., Ayli M., Ozcan M., et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002, 116:468-474.
15. Flomenberg N., Devine S.M., DiPersio J.F., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106:1867-1874.
16. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
17. DiPersio J.F., Micallef I.N., Stiff P.J., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773.
18. Calandra G., McCarty J., McGuirk J., et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008, 41:331-338.
19. Velasquez W.S., Cabanillas F., Salvador P., et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988, 71:117-122.
20. Brugger W., Henschler R., Heimfeld S., Berenson R.J., Mertelsmann R., Kanz L. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1994, 84:1421-1426.
21. Kantarjian H.M., O'Brien S., Smith T.L., et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000, 18:547-561.
22. Keeney M., Brown W., Gratama J., et al. Single platform enumeration of viable CD34+ cells. J Biol Regul Homeost Agents 2003, 17:247-253.
23. Riffenburgh Robert H. Statistics for Medicine 2006, Elsevier, New York. 2nd ed.
24. Musso M., Scalone R., Marcacci G., et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant 2010, 45:1147-1153.
25. Mills W., Chopra R., McMillan A., Pearce R., Linch D.C., Goldstone A.H. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995, 13:588-595.
26. Carella A.M., Palumbo G., Greco M., et al. TEAM (thiotepa, etoposide, cytarabine, melphalan) as conditioning regimen for lymphoma treatment with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2009, 43. Abstract 767.
27. Micallef I.N., Stiff P.J., DiPersio J.F., et al. Successful stem cell remobilization using plerixafor (Mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009, 15:1578-1586.
28. Tricot G., Cottler-Fox M.H., Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010, 45:63-68.
29. de la Rubia J., Blade J., Lahuerta J.J., et al. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica 2006, 91:621-627.
30. Morris C.L., Siegel E., Barlogie B., et al. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003, 120:413-423.
31. Hosing C., Saliba R.M., Okoroji G.J., et al. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol 2008, 19:1166-1171.
32. Mendrone A., Arrais C.A., Saboya R., Chamone Dde A., Dulley F.L. Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients. Transfus Apher Sci 2008, 39:187-192.
33. Canales M.A., Fernández-Jiménez M.C., Martín A., et al. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 2001, 86:494-498.
34. Haas R., Mohle R., Fruhauf S., et al. Patient characteristic associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994, 83:3787-3794.
35. Dreger P., Klöss M., Petersen B., et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995, 86:3970-3978.
36. Desikan K.R., Tricot G., Munshi N.C., et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 2001, 112:242-247.
37. Kuittinen T., Nousiainen T., Halonen P., Mahlamäki E., Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004, 33:907-912.
38. Paripati H., Stewart A.K., Cabou S., et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008, 22:1282-1284.
39. Dugan M.J., Maziarz R.T., Bensinger W.I., et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010, 45:39-47.
40. D'Addio A., Curti A., Worel N., et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011, 46:356-363.
41. Hübel K., Fresen M.M., Salwender H., et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011, 46:1045-1052.
42. Worel N., Rosskopf K., Neumeister P., et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 2011, 51:968-975.
43. Bensinger W., DiPersio J.F., McCarty J.M. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009, 43:181-195.
44. Tarella C., Cuttica A., Vitolo U., et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the Intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003, 97:2748-2759.
45. Gianni A.M., Bregni M., Siena S., et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997, 336:1290-1297.
46. Stiff P., Micallef I., McCarthy P., et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009, 15:249-256.
47. Olivieri A., Brunori M., Capelli D., et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004, 72:10-17.